Journal•ISSN: 2310-158X
Modern Rheumatology Journal
About: Modern Rheumatology Journal is an academic journal. The journal publishes majorly in the area(s): Rheumatoid arthritis & Medicine. It has an ISSN identifier of 2310-158X. Over the lifetime, 447 publications have been published receiving 984 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: The paper presents the new version of the clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice » prepared by the Association of Rheumatologists of Russia, the Russian Pain Society, and the Russian Gastroenterological Association, based on the results of well-organized clinical and large-scale population-based studies.
Abstract: The paper presents the new version of the clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice » prepared by the Association of Rheumatologists of Russia, the Russian Pain Society, the Russian Gastroenterological Association, the Russian Society of Cardiology, the Association of Traumatologists and Orthopedists of Russia, the Association of Interdisciplinary Medicine, and the Russian Association of Palliative Medicine. In our country, NSAIDs are the most important and most popular class of analgesics. Unlike global practice, Russian physicians rather rarely recommend paracetamol as a first-line drug to relieve moderate or severe pain, by giving preference to NSAIDs; the use of opioid analgesics for noncancers is minimized because of tight legal restrictions. NSAIDs are effective and easy-to-use; however, they are far from safe; the administration of these medications may lead to serious gastrointestinal, cardiovascular, renal, and other complications in a number of cases. So the use of NSAIDs should be compulsorily monitored for adverse reactions and the choice of a specific drug for each clinical case should be based on the objective estimation of a ratio of its efficacy to safety. In recent years, there have been fresh data on the use of NSAIDs for different diseases and a few novel representatives of this drug group have appeared on the Russian pharmacological market. This all has necessitated a new version of the guidelines on the rational use of NSAIDs. These are based on the provisions that have high validity and have been confirmed by the results of well-organized clinical and large-scale population-based studies, as well as by their meta-analysis. The guidelines are intended for physicians of all specialties.
42 citations
TL;DR: The paper presents in detail the prevalence of osteoarthritis (OA) and considers the predictors of disease development and progression and the clinical classification of OA and its place in the ICD-10.
Abstract: For the first time, the paper presents in detail the prevalence of osteoarthritis (OA) and considers the predictors of disease development and progression. The clinical classification of OA and its place in the ICD-10 are described. The clinical presentation of the disease is characterized in detail according to the localization of the process. It is noted that there is a change in the understanding of OA as a classic model of nociceptive pain. The paper depicts clinical, laboratory, and instrumental methods for diagnosing the disease, as well as classification and diagnostic criteria; much attention is paid to the current principles of OA therapy according to the Russian clinical recommendations and the guidelines of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the European League Against Rheumatism (EULAR).
35 citations
TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.
Abstract: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service.
19 citations
TL;DR: A large number of studies suggest that there is a serious shortage in care to patients with glucocorticoid-induced OP, which calls for effective measures to bring the real level of its prevention and treatment in compliance with the current clinical guidelines.
Abstract: Osteoporosis (OP) is a serious problem to patients who have long taken glucocorticoids. In the past two decade, much knowledge has been accumulated about the epidemiology of the disease and drugs with proven efficacy for its prevention and treatment have emerged. However, a large number of studies suggest that there is a serious shortage in care to patients with glucocorticoid-induced OP, which calls for effective measures to bring the real level of its prevention and treatment in compliance with the current clinical guidelines
18 citations
TL;DR: The paper considers the problems of endoprosthetic joint replacement in patients with rheumatoid arthritis receiving biological agents (BAs) and data on the safety of BAs used in the perioperative period are given.
Abstract: Endoprosthetic replacement is a widely used treatment for joint disease worldwide. In the past few decades, the rate of endoprosthetic replacement of different joints has substantially increased – about 1.5 million operations yearly. The paper considers the problems of endoprosthetic joint replacement in patients with rheumatoid arthritis (RA) receiving biological agents (BAs). The latter are extensively used to treat not only the early, but also late stages of the disease when there are already indications for endoprosthetic joint replacement, but the activity of the disease cannot be diminished by standard therapy with disease-modifying antirheumatic drugs. BA therapy can enhance the efficiency of monitoring the activity of RA in its different stages and improve functional parameters. There is an increase in the number of patients requiring endoprosthetic joint replacement and receiving BAs. Data on the safety of BAs used in the perioperative period are given. Endoprosthestic joint replacement during this therapy makes it possible to decrease the degree of pain syndrome, to improve the function of an operated joint and the quality of life in patients, to affect the course of RA, to lower disease activity, and to improve their monitoring.
17 citations